Trials / Recruiting
RecruitingNCT03435796
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
- Status
- Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 1,541 (estimated)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | Gene-modified (GM) T cell therapy | No investigational product will be administered |
Timeline
- Start date
- 2018-07-19
- Primary completion
- 2036-11-30
- Completion
- 2036-11-30
- First posted
- 2018-02-19
- Last updated
- 2026-03-04
Locations
200 sites across 20 countries: United States, Australia, Austria, Belgium, Canada, Finland, France, Germany, Israel, Italy, Japan, Netherlands, Norway, Poland, Romania, South Korea, Spain, Sweden, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03435796. Inclusion in this directory is not an endorsement.